FTM
TYRA icon

First Turn Management’s Tyra Biosciences TYRA Stock Holding History

First Turn Management’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-381,210
Closed -$6.25M – 41
2024
Q1 		$6.25M Buy
+381,210
New +$6.25M 0.94% 33

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $76.1M AUM 638.59% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

First Turn Management's TYRA Position: Q2 2024 in Review

First Turn Management sold out of Tyra Biosciences (TYRA) in Q2 2024, closing a stake of 381,210 shares — an estimated $6.25M sold.

First Turn Management first reported a position in TYRA in Q1 2024 and held it in 1 quarter. The position peaked at $6.25M in Q1 2024. 79 funds tracked by Wall St. Rank hold TYRA as of Q2 2024.

  • First Turn Management reported no remaining Tyra Biosciences position as of Q2 2024 after selling out during the quarter.
  • First Turn Management sold 381,210 Tyra Biosciences shares in Q2 2024, an estimated $6.25M.
  • First Turn Management first reported a position in Tyra Biosciences in Q1 2024 and held it in 1 quarter.
  • First Turn Management's Tyra Biosciences position peaked at $6.25M in Q1 2024.
  • 79 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2024.

Based on First Turn Management's 13F filing for Q2 2024, filed 8 Aug 2024.